Omega Therapeutics, Inc. (OMGA)
NASDAQ: OMGA · Real-Time Price · USD
0.790
+0.030 (3.97%)
At close: Nov 20, 2024, 4:00 PM
0.810
+0.020 (2.56%)
Pre-market: Nov 21, 2024, 4:11 AM EST
Omega Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 8.1 | 3.09 | 2.07 | 0.14 | - | - |
| Revenue Growth (YoY) | 185.04% | 49.25% | 1339.58% | - | - | - |
| Cost of Revenue | 12.06 | 65.87 | 77.27 | 47.87 | 21.06 | - |
| Gross Profit | -3.97 | -62.78 | -75.19 | -47.72 | -21.06 | - |
| Selling, General & Admin | 29.02 | 37.49 | 27.57 | 18.31 | 7.58 | 5.41 |
| Research & Development | 41.16 | - | - | - | - | 11.93 |
| Operating Expenses | 70.18 | 37.49 | 27.57 | 18.31 | 7.58 | 17.34 |
| Operating Income | -74.15 | -100.26 | -102.77 | -66.03 | -28.65 | -17.34 |
| Interest Expense | -1.8 | -1.8 | -1.3 | -1 | -0.78 | -0.6 |
| Interest & Investment Income | 2.93 | 4.61 | 1.52 | 0.09 | 0 | - |
| Other Non Operating Income (Expenses) | -0.07 | 0.02 | -0.16 | -1.34 | -0.03 | -0.01 |
| Pretax Income | -73.09 | -97.43 | -102.7 | -68.28 | -29.45 | -17.95 |
| Net Income | -73.09 | -97.43 | -102.7 | -68.28 | -29.45 | -17.95 |
| Net Income to Common | -73.09 | -97.43 | -102.7 | -68.28 | -29.45 | -17.95 |
| Shares Outstanding (Basic) | 55 | 54 | 48 | 22 | 4 | 3 |
| Shares Outstanding (Diluted) | 55 | 54 | 48 | 22 | 4 | 3 |
| Shares Change (YoY) | 5.63% | 12.80% | 113.71% | 473.56% | 17.69% | - |
| EPS (Basic) | -1.33 | -1.80 | -2.14 | -3.05 | -7.54 | -5.41 |
| EPS (Diluted) | -1.33 | -1.80 | -2.14 | -3.05 | -7.54 | -5.41 |
| Free Cash Flow | -57.64 | -94.38 | -99.9 | -59.08 | -27.94 | -16.56 |
| Free Cash Flow Per Share | -1.04 | -1.75 | -2.09 | -2.64 | -7.15 | -4.99 |
| Operating Margin | -916.01% | -3240.50% | -4957.36% | -45855.56% | - | - |
| Profit Margin | -902.93% | -3148.93% | -4954.22% | -47416.67% | - | - |
| Free Cash Flow Margin | -712.04% | -3050.39% | -4818.86% | -41025.00% | - | - |
| EBITDA | -72.41 | -98.69 | -101.2 | -64.65 | -27.5 | -16.55 |
| D&A For EBITDA | 1.74 | 1.57 | 1.56 | 1.39 | 1.15 | 0.79 |
| EBIT | -74.15 | -100.26 | -102.77 | -66.03 | -28.65 | -17.34 |
Source: S&P Capital IQ. Standard template.
Financial Sources.